Neuland Laboratories has commenced commercial production of additional capacities at its Unit 1 and Unit 3 manufacturing facilities in Telangana. The operational milestone follows earlier expansion plans disclosed to investors and marks the realization of capacity additions intended to support the company’s growth trajectory. The announcement was made via a regulatory filing on July 31, 2026.

The notification was issued pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Neuland Laboratories informed both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Ltd (NSE) of the status update. The filing references previous communications dated August 1, 2024, and January 21, 2025, which outlined the progress of these expansion initiatives.

Facility Details

The commercial production has started at two specific locations within the Sangareddy District of Telangana:

Both facilities are now producing commercially at the additional capacities planned under the respective expansion projects. The commencement indicates that the infrastructure upgrades and regulatory clearances for these specific capacity additions have been successfully completed.

Strategic Implications

The ramp-up of production at Unit 1 and Unit 3 is a key operational development for Neuland Laboratories. By bringing additional capacity online, the company aims to enhance its manufacturing output capabilities. This expansion supports the firm’s ability to meet growing demand for its pharmaceutical products and active pharmaceutical ingredients (APIs). The timely execution of these projects reflects the management’s focus on scaling operations efficiently.

Sarada Bhamidipati, Company Secretary of Neuland Laboratories Limited, signed the intimation letter. The filing serves as a formal record for stakeholders and regulators regarding the company’s operational progress. No financial figures or specific volume metrics were disclosed in this particular announcement.

Neuland Laboratories Limited will host its Q1FY27 earnings conference call on August 5, 2026, at 17:30 IST. The company announced the schedule to provide investors with an opportunity to discuss its financial performance for the quarter ended June 30, 2026. This disclosure ensures transparency regarding the firm's operational and financial outcomes for the initial period of the fiscal year.

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015. Neuland Laboratories Limited submitted the intimation to both the Bombay Stock Exchange and the National Stock Exchange of India Ltd on July 28, 2026. The filing was signed by Sarada Bhamidipati, the Company Secretary, confirming the details for regulatory records.

Call Details

Investors interested in participating in the earnings discussion must register through the official link provided by the company. The webcast will allow stakeholders to hear management commentary on the quarterly results. Key details of the event are outlined below:

About Neuland Laboratories

Neuland Laboratories Limited is a manufacturer of Active Pharmaceutical Ingredients (APIs) with over four decades of industry experience. The company operates cGMP manufacturing facilities and serves customers in approximately 80 countries. It has developed more than 300 processes and 100 APIs, supported by around 1,010 regulatory filings across the US, European Union, and other geographies.

The firm holds cGMP certifications from major health authorities including the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, and Health Canada. Additional certifications include ISO 9001, ISO14001, OHSAS18001, and ISO 27001.

For further queries, investors may contact the Investor Relations team at ir@neulandlabs.com or reach out to Runjhun Jain and Minakshi Machutre at EY.